SCHEMBL3010484

SCHEMBL3010484

CCc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(Cl)c(Cl)c4)CC3)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.42
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
AR P10275 1/20 0.34
NFE2L2 Q16236 1/20 0.34
DNM1L O00429 2/20 0.33
ALDH1A1 P00352 2/20 0.33
KDM2B Q8NHM5 2/20 0.33
OGA O60502 1/20 0.33
TP53 P04637 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HTR7 P34969 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
GHSR Q92847 1/20 0.33
ERBB2 P04626 1/20 0.33
EPHA2 P29317 1/20 0.33
KDR P35968 1/20 0.33
EPHB4 P54760 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3022148 0.93 LMNA (0.36) THRBLMNAL3MBTL1ARNFE2L2
SCHEMBL3016660 0.93 GBA1 (0.38) THRBLMNAL3MBTL1ARDNM1L
SCHEMBL3017117 0.92 MAPT (0.38) LMNAL3MBTL1ARNFE2L2KDM2B
SCHEMBL3013801 0.92 L3MBTL1 (0.39) THRBLMNAL3MBTL1ARNFE2L2
SCHEMBL3020208 0.92 DRD2 (0.35) THRBL3MBTL1DNM1LALDH1A1OGA
SCHEMBL3015155 0.90 HTR2A (0.41) LMNAL3MBTL1ARDNM1LSMN1; SMN2
SCHEMBL3011356 0.90 MAPT (0.39) LMNAL3MBTL1TP53SMN1; SMN2
SCHEMBL2997801 0.90 SMN1; SMN2 (0.39) LMNAL3MBTL1ALDH1A1SMN1; SMN2HTR7
SCHEMBL3014774 0.89 VCAM1 (0.40) THRBLMNAL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL3019243 0.89 L3MBTL1 (0.38) LMNAL3MBTL1ARNFE2L2DNM1L

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA THRB 2628/4885LMNA 80/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.